Background: Desmopressin (DDAVP) is used in patients with moderate/mild hemophilia A (PWMHs) to increase their factor VIII (FVIII) level and, if possible, normalize it. However, its effectiveness varies between individuals. The GIDEMHA study aims to investigate the influence of gene variants.
View Article and Find Full Text PDFIntroduction: Dominant-negative effects have been described for 10 F11 variants in the literature.
Aim: The current study aimed at identifying putative dominant-negative F11 variants.
Material And Methods: This research consisted in a retrospective analysis of routine laboratory data.